Drug-resistant infections: fast tests and new antibiotics, with India at the centre
Antibiotics are failing fastest in South Asia, new drugs are scarce, and doctors lack quick tests. India has shown it can discover a new antibiotic; the bigger near-term gap is fast diagnosis.
Seedhi baat: Dawaiyan kaam karna band kar rahi hain, sabse zyada South Asia me. Nayi dawa kam hain aur jaldi test nahi milte. India ke liye fast test ka mauka bada hai.
Fact sourced, with link and check date (click [id]). Analysis NitiMarg's reading, not a fact.
1. The world's development challenge
- FactWHO's 2025 surveillance report (over 23 million lab-confirmed infections from 104 countries) found that about 1 in 6 common bacterial infections in 2023 were resistant to antibiotics; in WHO's South-East Asia region it was about 1 in 3.[H1][H2]
- FactBetween 2018 and 2023, resistance rose in over 40% of the antibiotic combinations WHO monitors, by 5-15% a year on average.[H2]
- FactWHO estimates 55.2% of K. pneumoniae bloodstream infections globally resist third-generation cephalosporins; in the South-East Asia region, 41.2% of K. pneumoniae bloodstream infections resist carbapenems, a last-line drug class.[H9]
- FactThe Lancet GRAM study estimates 1.14 million deaths were directly caused by resistant bacteria in 2021 and forecasts 39.1 million such deaths between 2025 and 2050; South Asia carries the largest forecast share (11.8 million).[H3]
2. The real technology challenge
- FactWHO's 2025 pipeline review: antibacterials in clinical trials fell from 97 (2023) to 90. Only 15 are innovative and only 5 work against at least one 'critical' priority bacterium. Of 17 new antibacterials approved since July 2017, only 2 are a new chemical class.[H4]
- FactThe early-stage pipeline (232 programmes) is fragile: 90% of the companies involved are small firms with fewer than 50 employees.[H4]
- FactWHO's diagnostics review finds no multiplex platform suited to intermediate (level II) labs that can identify bloodstream infections directly from whole blood without culture, poor access to tests like CRP and procalcitonin that tell bacterial from viral infection, and too few simple point-of-care tests.[H4]
3. Where scientists are stuck stage today
Science advancing, but the drug pipeline is thin and frontline tests are missing
- FactGRAM estimates 11.1 million deaths could be averted between 2025 and 2050 with a new Gram-negative drug pipeline, and far more (92 million) through better care of severe infections and access to antibiotics.[H3]
- AnalysisRead together: new drugs matter, but faster diagnosis and right-drug-first-time care are where the largest, quickest gains are.
4. What researchers are trying now
- FactWHO counts 40 'non-traditional' antibacterial approaches in trials, such as bacteriophages, antibodies and microbiome-modulating agents.[H4]
- FactIndia's first indigenously developed antibiotic, nafithromycin (brand Miqnaf, by Wockhardt with support from DBT's BIRAC), took 14 years and Rs 500 crore; it is a 3-day treatment for drug-resistant community pneumonia. PIB notes India bears 23% of the world's community pneumonia burden.[H5]
- FactIndia's drug regulator CDSCO approved Miqnaf for adult community-acquired bacterial pneumonia (company release, 2 January 2025); Wockhardt reports launching it on 27 May 2025.[H6][H7]
- FactIndia launched its National Action Plan on AMR 2.0 (2025-29) on 18 November 2025, with ministry-wise action plans, timelines and budgets, stronger lab capacity and infection control, and more private-sector engagement.[H8]
5. India's angle
- AnalysisIndia is both the place where the problem is heaviest (South-East Asia and South Asia figures above) and a proven drug maker, now with its own new antibiotic. That combination is rare.
- AnalysisNAP-AMR 2.0 explicitly asks for more lab capacity and private-sector involvement, which opens doors for diagnostic and lab-service startups in district hospitals and small labs.
6. The opportunity for India
Fast 'bacterial or not, and which drug works' testing for district hospitals and small labs
Who can do it: Diagnostics startups, lab chains, microbiologists and biomedical engineers; also medical-device MSMEs.
- AnalysisOffer a bundled service for level II labs and district hospitals: rapid CRP/procalcitonin screening, faster susceptibility testing, and simple software that reports resistance trends back to doctors and to national surveillance.
First steps
- AnalysisStart as a lab-service network using already-approved test kits, not a new device; prove turnaround time and cost per patient.
- AnalysisPilot with one district hospital and link results to stewardship advice.
- AnalysisOnly later develop own devices, aligned with the WHO diagnostic gaps listed above.
7. Risks and what could go wrong
- AnalysisMedical-device and lab rules need careful compliance; clinical validation takes time and money.
- AnalysisHospitals are price-sensitive; the test must save money on wrong antibiotics and bed-days to sell.
- AnalysisLarge global diagnostics companies already sell in India; a startup must win on cost, service and reach.
Score 84 of 100 NitiMarg analysis (andaaza), same 5-rating formula as the opportunity list.
Formula: round((0.25*P + 0.25*D + 0.25*C + 0.10*E + 0.15*I) / 5 * 100). Confidence: Medium.
Sources all opened on 14 Nov 2026
- [H1] Global antibiotic resistance surveillance report 2025 (GLASS)
World Health Organization · published 2025-10-13 · opened and checked 14 Nov 2026 - [H2] WHO warns of widespread resistance to common antibiotics worldwide
PAHO/WHO · published 2025-10-13 · opened and checked 14 Nov 2026 - [H3] Global burden of bacterial antimicrobial resistance 1990-2021, with forecasts to 2050 (GRAM)
The Lancet (GBD 2021 AMR Collaborators), open-access copy on PubMed Central · published 2024-09 · opened and checked 14 Nov 2026 - [H4] WHO releases new reports on new tests and treatments in development for bacterial infections
World Health Organization · published 2025-10-02 · opened and checked 14 Nov 2026 - [H5] New antibiotic offers 10x efficacy with just 3 doses to combat drug-resistant pneumonia
PIB (Ministry of Science & Technology) · published 2024-11-20 · opened and checked 14 Nov 2026 - [H6] Indian drug regulator approves Wockhardt's Miqnaf (nafithromycin) for CABP
Wockhardt (company press release) · published 2025-01-02 · opened and checked 14 Nov 2026 - [H7] Wockhardt Q4 FY25 results release (Miqnaf launch on 27 May 2025)
Wockhardt (company press release) · published 2025-05 · opened and checked 14 Nov 2026 - [H8] Union Health Minister launches NAP-AMR 2.0 (2025-29)
PIB (Ministry of Health & Family Welfare) · published 2025-11-18 · opened and checked 14 Nov 2026 - [H9] Global antibiotic resistance surveillance report 2025 (full report, PDF)
World Health Organization (IRIS) · published 2025-10 · opened and checked 14 Nov 2026